Breaks Categories: News

MondayAug 28, 2017 10:30 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Outlines Plans to Launch First Chinese Daily Video News Broadcast Focused on Cryptocurrency

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced its plans to launch the first Chinese daily video news broadcast from the NYSE covering digital currency and its underlying blockchain technology. The videos will be produced by independent news agency Wall Street Multimedia (“WSM”) and are expected to begin airing in October, providing exclusive analysis and timely information regarding all aspects of the emerging digital currency world. “I have been following the progression of the cryptocurrency market closely since 2014,” Warren Wang, founder and CEO of CIIX, stated in the news release. “Since January 2015, the price of bitcoin…

Continue Reading

MondayAug 28, 2017 9:54 am

NetworkNewsBreaks – PotNetwork Holding, Inc. (POTN) Takes Center Stage at Mayweather-McGregor with Sponsorship Deal

PotNetwork Holding, Inc. (OTC: POTN) this morning announced that its wholly-owned subsidiary, Diamond CBD, Inc., was an official sponsor of two contenders at the Mayweather-McGregor Event that took place on August 26. “We want to thank Francisco Fonseca and Steve Cunningham for the opportunity to gain this monumental level of brand exposure,” Gary Blum, chief executive officer of PotNetwork Holding, stated in the news release. “In consideration of what is paid for a 30 second commercial spot, during a comparable sporting event, we believe that this is one of the most exciting opportunities for public exposure that Diamond CBD and…

Continue Reading

MondayAug 28, 2017 9:13 am

NetworkNewsBreaks – ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Announces Release of High Level CBD Product

ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced the release of one of Canada’s highest legal CBD:THC ratio products by wholly-owned subsidiary ABcann Medicinals Inc. CBD-Med has a ratio of 27.6:1 (18.5% CBD to 0.67% THC), making it one of Canada’s highest CBD products under Health Canada regulations. “The development of these products is in line with ABcann's corporate strategy as a premium product provider of organic, pesticide free cannabis,” Ken Clement, executive chairman of ABcann, stated in the news release. “As the Company continues to scale production capacity, our product line will expand as we strive to…

Continue Reading

ThursdayAug 24, 2017 12:29 pm

NetworkNewsBreaks – Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) Obtains FDA Clearance to Commence Clinical Study of Parkinson’s Disease Treatment

Shares of Titan Pharmaceuticals (NASDAQ: TTNP) are 5% higher after the company this morning said its Investigational New Drug (IND) application for its ropinirole implant has been cleared by the U.S. Food and Drug Administration (FDA). The company is now permitted to move forward with the phase 1/2 clinical study in patients. Developed utilizing Titan's ProNeura™ technology, the ropinirole implant is intended for the long-term, continuous delivery of ropinirole HCL for the treatment of signs and symptoms of Parkinson's disease. "Our ropinirole implant is designed to provide continuous, non-fluctuating therapeutic levels of medication for up to three months, potentially offering…

Continue Reading

ThursdayAug 24, 2017 12:26 pm

NetworkNewsBreaks – Origin Agritech (NASDAQ: SEED) Collects First Payment of RMB 152M for Commercial Seed Business Sale; Shares Surge

Origin Agritech (NASDAQ: SEED) shares are up 9% after the company said it has received the first payment of RMB 152 million from its RMB 421 million sale of its proprietary China-based commercial corn seed production and distribution business. Per the agreement, Origin will preserve its corn breeding and biotech research programs; all intellectual properties; GM trait portfolio and modern laboratories; extensive field testing networks; and off-season winter nursery in Hainan. The company will also uphold its "Green Pass" status, which grants the company the advantage of introducing new hybrid varieties to the Chinese market through an expedited government approval…

Continue Reading

ThursdayAug 24, 2017 12:22 pm

NetworkNewsBreaks – Identiv, Inc. (NASDAQ: INVE) Expands Partnership with PSA Security Network with New Physical Security Solutions Distribution Deal

Identiv (NASDAQ: INVE) this morning said it has expanded its partnership with PSA Security Network (PSA) to distribute the company’s full suite of Hirsch physical access control system (PACS) and security management solutions. The distribution agreement includes Hirsch Velocity Software, Hirsch Mx Controllers, Hirsch ScramblePad Reader Family, uTrust TS Reader Family, and uTrust TS Cards. “This expanded partnership with PSA provides our end-user base with a network of highly qualified security systems integrators that can offer installation and support services in a consistent and professional manner to key markets across the country,” Identiv VP of marketing and business development John…

Continue Reading

ThursdayAug 24, 2017 9:16 am

NetworkNewsBreaks – PotNetwork Holdings, Inc. (POTN) Subsidiary Achieves 30% Month-Over-Month Revenue Growth in July

PotNetwork Holdings, Inc. (OTC: POTN) this morning announced that its wholly owned subsidiary, Diamond CBD, Inc., has delivered a considerable month-over-month increase in revenues, recording $1,459,137 for the month of July. This total exceeded the company’s June revenues by more than 30 percent. “We are very pleased with how the numbers have continued to gain over the summer,” Maria Gomez, regional vice president of sales for Diamond CBD, Inc., stated in the news release. “We are consistently setting new sales records month after month and are excited to be able to report this type of continuing growth. We have taken…

Continue Reading

WednesdayAug 23, 2017 1:55 pm

NetworkNewsBreaks – Tandem Diabetes Care, Inc. (NASDAQ: TNDM) Sets Launch of t:lock™ Connector for its Insulin Pump Cartridges and Infusion Sets

Tandem Diabetes Care (NASDAQ: TNDM) this morning said it is preparing to launch its t:lock™ connector for its insulin pump cartridges and infusion sets, with the gradual rollout set to begin September 5. Additionally, all infusion sets currently offered by Tandem will be made available with the new t:lock connector and the company expects to fully transition by the end of 2017. The t:lock versions of Tandem’s current infusion sets will be sold under the brand names AutoSoft™, VariSoft™ and TruSteel™. “This launch strengthens our overall insulin delivery systems, addressing one of our customers’ most frequent requests to make the…

Continue Reading

WednesdayAug 23, 2017 12:34 pm

NetworkNewsBreaks – Celldex Therapeutics, Inc. (NASDAQ: CLDX) Completes Patient Enrollment in METRIC Study

Celldex Therapeutics (NASDAQ: CLDX) this morning said that it has completed patient enrollment in its phase 2b METRIC study of glembatumumab vedotin (glemba) in patients with metastatic triple negative breast cancers that overexpress gpNMB. The antibody-drug conjugate, glemba, works by targeting and binding to the protein expressed by multiple tumor types, gpNMB. The company expects that topline primary endpoint data will be reported in the second quarter of 2018. "Patients with triple negative breast cancer have very limited treatment options. We believe glemba holds significant promise as a potential new targeted treatment for patients with this devastating disease and look…

Continue Reading

WednesdayAug 23, 2017 12:32 pm

NetworkNewsBreaks – Novavax, Inc.’s (NASDAQ: NVAX) Preclinical NanoFlu™ Study Published in Vaccine

Shares of Novavax (NASDAQ: NVAX) are up 4% following the company’s news that data from a preclinical study have been published in the journal, ‘Vaccine.’ The preclinical study of the company’s influenza vaccine candidate with its proprietary Matrix-M™ adjuvant, NanoFlu™, suggests that NanoFlu has the potential to provide a stronger immune response than influenza vaccines currently available to older adults. “The data in this publication further validate our nanoparticle vaccine platform and provide a strong rationale for advancing NanoFlu into a Phase 1/2 clinical trial. Our goal is to deliver a superior, differentiated vaccine to the greater than $3 billion…

Continue Reading